PNP Therapeutics

Name

PNP Therapeutics

Legal name

PNP Therapeutics, Inc.

Website

https://pnptherapeutics.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

Keywords

• Cancer gene therapy
• Purine nucleoside phosphorylase
• Prodrug activation therapy
• Adenoviral vector therapy
• Head and neck cancer treatment

Headquarters

HQ city

Birmingham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Licensing Royalties: On September 28, 2021, PNP entered into an Assignment and License Agreement with GeoVax, Inc., whereby GeoVax obtained an exclusive license to PNP's intellectual property and related assets associated with Gedeptin. PNP generates revenue through licensing fees and potential royalties from GeoVax.
2. Pharmaceutical Partnership: Pre-revenue clinical-stage company currently seeking pharmaceutical industry partners for continued clinical development and commercialization of Gedeptin platform technology.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

PNP Therapeutics is a clinical-stage biopharmaceutical company developing Gedeptin, a proprietary gene-therapy platform that uses an adenoviral vector to deliver the E. coli purine nucleoside phosphorylase (PNP) gene into solid tumors. Once expressed, the enzyme converts the systemic prodrug fludarabine phosphate into potent fluoroadenine chemotherapy confined within the tumor mass, targeting head and neck cancers and other refractory solid tumors. The company's primary commercial activity is out-licensing its gene-therapy IP and related assets to pharmaceutical partners (executed via the September 2021 Assignment and License Agreement with GeoVax, Inc.).

Product overview

PNP Therapeutics is a clinical-stage biopharmaceutical company developing Gedeptin, a platform technology based on E. coli purine nucleoside phosphorylase (PNP) enzyme. The system works by delivering an adenoviral vector (Ad/PNP) expressing the PNP gene directly into tumors, followed by systemic administration of fludarabine phosphate (F-araAMP). The PNP enzyme converts F-araAMP into fluoroadenine, a highly potent chemotherapy that kills tumor cells and surrounding cells through a novel mechanism of action targeting both dividing and non-dividing cells. The technology was originally licensed to GeoVax in September 2021.

Differentiator

Problem solved

Functional benefit

Brands

• Gedeptin: A platform technology (adenoviral vector expressing E. coli purine nucleoside phosphorylase gene) for the intratumoral treatment of cancer, particularly head and neck cancers.

Products and services

• Gedeptin Gedeptin is an adenoviral vector expressing the E. coli purine nucleoside phosphorylase (PNP) gene, administered by intratumoral injection into solid tumors (initially head and neck cancers), followed by systemic fludarabine phosphate. The expressed PNP enzyme converts the prodrug into potent fluoroadenine chemotherapy confined within the tumor mass. It is the company's lead clinical-stage product candidate and has received FDA orphan drug designation for anatomically accessible oral and pharyngeal cancers. The Gedeptin IP and related assets are exclusively licensed to GeoVax, Inc. as of September 2021.

Quantifiable outcome

• Phase I trial: 11 patients completed therapy without serious adverse events; stable disease in 5 of 6 tumors in cohorts 1 and 2; complete responses in 2 patients and partial responses in cohorts 3 and 4
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• GeoVax, Inc.coreOEM/ Whitelabel/ Licensing Partner · 28 September 2021On September 28, 2021, PNP entered into an Assignment and License Agreement with GeoVax, Inc., whereby GeoVax obtained an exclusive license to PNP's intellectual property and related assets associated with Gedeptin. All inquiries concerning Gedeptin should now be directed to GeoVax. This was a key strategic licensing arrangement for commercialization of the company's lead product.
• Southern Research InstitutecoreStrategic or Co-development PartnerSouthern Research Institute developed the gene-therapy technology in collaboration with UAB scientists. The institute is co-owner of the patent portfolio and initial investor. Well-known for discovering numerous FDA-approved anti-cancer drugs and successful spin-out of Brookwood Pharmaceuticals.
• University of Alabama at Birmingham (UAB)coreStrategic or Co-development PartnerUAB scientists Eric Sorscher and William Parker co-discovered the PNP technology. The UAB Research Foundation is co-owner of the patent portfolio and conducted Phase I clinical trials. UAB received patent allowance in September 2013.

Scale indicators6 records

Recent moves7 records

Expansion highlights4 records

Market position

Competitive moat3 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pnp-therapeutics-inc-

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds7 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PNP Therapeutics